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OBJECTIVES The aim of the study was to investigate whether omega-3 fatty acids (n-3 FA) reduce the
occurrence of restenosis after percutaneous transluminal coronary angioplasty.
BACKGROUND Meta-analyses have shown significant reduction of restenosis after coronary angioplasty upon
supplementation with n-3 FA.
METHODS In a prospective, placebo-controlled, double-blind study, 500 patients were randomly
allocated to treatment with n-3 FA (Omacor™, Pronova AS, Oslo, Norway) 5.1 g/day or
corn oil (placebo) starting at least two weeks prior to elective coronary angioplasty. The
treatment was continued until restenosis evaluation by quantitative coronary angiography
after six months. Stenosis was defined as a minimal luminal diameter (MLD) ,40% of the
reference diameter. Successful coronary angioplasty was defined as $20% acute gain in MLD
and a residual stenosis ,50%. Restenosis was defined as $20% late loss of diameter and
stenosis .50% or an increase in stenosis of $0.7 mm. Three-hundred ninety-two patients
fulfilled the criteria for initial stenosis and successful coronary angioplasty, and, except four
patients who died, none were lost for follow-up.
RESULTS Restenosis occurred in 108/266 (40.6%) of the treated stenoses in the Omacor group and in
93/263 (35.4%) in the placebo group (odds ratio [OR] 1.25, 95% confidence interval [CI]
[0.87–1.80] p 5 0.21). In the Omacor group one or more restenoses occurred in 90/196
(45.9%) patients as compared with 86/192 (44.8%) in the placebo group (OR 1.05, 95% CI
[0.69–1.59] p 5 0.82).
CONCLUSIONS Supplementation with 5.1 g n-3 FA/day for six months, initiated at least two weeks prior to
coronary angioplasty did not reduce the incidence of restenosis. (J Am Coll Cardiol 1999;33:
1619–26) © 1999 by the American College of Cardiology
Percutaneous transluminal coronary angioplasty was intro-
duced in 1977 (1) and has become the most used invasive
procedure for myocardial revascularization. This procedure
gives high initial success rate with an immediately good
blood flow in the affected artery (2). The major concern is
the high incidence of restenosis, which has recently been
documented to be as high as 45% four to six months after
coronary angioplasty, when measured with quantitative
coronary angiography (3,4). The process of restenosis is
initiated by injury of the vessel wall with the subsequent
release of thrombogenic, vasoactive and mitogenic factors
(5).
Endothelial and deep-vessel wall injury lead to platelet
aggregation, fibrin formation, inflammation and activation
of macrophages and vascular smooth-muscle cells. These
events induce the production and release of growth factors
and cytokines (6), resulting in the migration of smooth
muscle cells from their usual location in the arterial media to
the intima. At the same time they change to a synthetic
phenotype, produce extracellular matrix and proliferate
(7,8). This process eventually results in lumen narrowing
and represents the restenosis. In addition, remodelling of
the vascular wall seems to play a role for the ultimate degree
of restenosis (9).
With focus on smooth muscle cell proliferation and
matrix formation, numerous pharmacological approaches
have been evaluated in an attempt to prevent restenosis.
Except for promising results with the antioxidant probucol
(10), no single principle has consistently shown a reduction
in angiographically defined restenoses at six months.
Omega-3 fatty acids (n-3 FA) have been proposed to be
antiatherogenic through a variety of mechanisms, like de-
crease in membrane arachidonic acid and thromboxane A2
formation with decreased platelet aggregation, decreased
production of platelet derived growth factor in endothelial
cells (11) and anti-inflammatory properties (12). Further-
more, reduction of intimal hyperplasia and coronary athero-
sclerosis in animal models has been observed upon admin-
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istration of n-3 FA (13–15), as well as reduced incidence of
aortocoronary vein graft occlusion in humans (16). How-
ever, clinical trials previously conducted to determine the
effect of n-3 FA on the restenosis rate after coronary
angioplasty have produced conflicting results (3,4,17–25).
Two meta-analyses have been published (26,27), con-
cluding with a small to moderate benefit of n-3 FA on
restenosis. In 1994 Leaf et al. published a large multicenter,
double-blind, placebo-controlled study. They concluded
that 8 g/day of n-3 FA failed to prevent the high rate of
restenosis after coronary angioplasty (4).
We report the results of a prospective randomized,
placebo-controlled, double-blind trial (the Coronary An-
gioplasty Restenosis Trial, CART) designed to test the
hypothesis that a dietary supplementation of n-3 FA given
daily from two weeks before through six months after
angioplasty will reduce the frequency of restenosis.
METHODS
Study design and patient population. From April 1992
through February 1996, 500 patients accepted for elective
percutaneous transluminal coronary angioplasty were sched-
uled to receive a daily dietary supplement of 3 3 1 g gelatin
capsules twice daily, starting at least two weeks prior to
coronary angioplasty and continued until follow-up angiog-
raphy regularly six months after the angioplasty. Each
capsule containing 84% ethyl esters of n-3 polyunsaturated
fatty acids (0.45 g eicosapentaenoic acid [EPA] and 0.39 g
docosahexaenoic acid [DHA] with the addition of 4 mg
alpha-tocopherol) (Omacor™, Pronova AS, Oslo, Norway)
or an equal amount of ethyl ester of corn oil as placebo.
Randomization was undertaken using consecutively num-
bered sealed envelopes. Both the patients and the investi-
gators were blinded with regard to the treatment given.
Compliance with the study medication was assessed by
determination of serum phospholipid fatty acids before and
at the end of the study period and by capsule counts.
A previously validated individual diet questionnaire (28)
was obtained from 261 consecutively included patients. All
patients were recruited from a single center, and they were
treated with other medication as prescribed by their physi-
cian. At randomization, users of fish oil supplementation
were asked to stop the additional intake during the study
period. The major type (29) and the location of the index
lesion in the vessel were characterized. All treated lesions
were in vessels with a diameter above 1.5 millimeters (mm),
and the mean value was 2.7 mm. No differences in the
diameter of treated vessels were found between the treat-
ment groups. Patients who were scheduled for elective
coronary angioplasty for one or more lesions in native
coronary arteries who had not undergone prior angioplasty
and were willing to participate were candidates for inclu-
sion.
Exclusion criteria were: questionable patient compliance;
treatment with steroid or immunosuppressive drugs; poorly
controlled, sustained hypertension; pregnancy; unstable an-
gina pectoris; bleeding disorder documented by laboratory
tests; or other serious illnesses with expected survival of less
than two years. Angiographic reasons for exclusion were
diffuse lesions (.2 cm long), excessive tortuosity of proxi-
mal segment, extremely angulated segments (.90°) or
chronic (.3 months) total occlusions. Stent implantation
was reason for exclusion because of the special therapeutic
regimen given after this procedure.
Coronary angioplasty procedure. All patients underwent
coronary angioplasty from the right femoral artery using a
rapid exchange system. A standard regimen of drug treat-
ment was instituted before the procedure. The patients were
started or maintained on aspirin 160 mg once daily, and
those who did not use any calcium channel blocking drugs
received 20 mg nifedipine twice daily at least from the day
before angioplasty. Patients were in the fasting state. They
were also pretreated with an infusion of glyseroltrinitrate
12–25 mg per min which was continued throughout the
procedure, and the patients were heparinized with a bolus
dose of 10,000 I.E. intra-arterially followed by 5,000 I.E.
every hour during the angioplasty. Thereafter intravenous
infusions of heparin 1,000 I.E./h, and glyseroltrinitrate
12 mg per min were continued until the next day.
Coronary cineangiograms of the lesion on the affected
vessels were obtained using two orthogonal views. (General
Electric CGR DX HILINE Buc, France). To enable
replication, all angles and positions of gantry were noted in
a specific protocol. The angiograms performed before cor-
onary angioplasty, immediately after coronary angioplasty
and at follow-up examinations were obtained in the same
catheterization site with the same angiographic equipment
and the same image intensifier magnification.
Each cardiac catheterization procedure was standardized,
and only two experienced radiologists were involved in the
study. Quantitative measurements were calibrated using the
guiding catheter as the reference dimension. The localiza-
tion of the marker of minimal luminal diameter (MLD) was
determined by the radiologist according to the lowest figure
of MLD given by the computer. In addition to the standard
projections, the best camera angles for visualization of
stenotic areas were recorded for reproducible positioning on
Abbreviations and Acronyms
CI 5 confidence interval
CART 5 Coronary Angioplasty Restenosis Trial
DHA 5 docosahexaenoic acid
EPA 5 eicosapentaenoic acid
EMPAR 5 Enoxaparin MaxEPA Prevention of
Angioplasty Restenosis
MLD 5 minimal luminal diameter
NYHA 5 New York Heart Association
OR 5 odds ratio
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subsequent filming. Angiographic controls between the
angioplasty and the study end point, was not conducted
unless recurrence of severe ischemic symptoms emerged. In
all other patients repeated angiography was performed at six
months. If a repeat angiogram was indicated at four months
or later, no further angiogram was requested at six months.
On discharge after the coronary angioplasty the patients
were maintained on trial medication and other therapy as
individually indicated for the following six months. Inter-
pretation of the angiographies was undertaken without
knowledge of the patients assigned treatment.
Angiographic definitions. A qualifying stenosis was de-
fined as an atherosclerotic lesion in the coronary arteries
equal to or more than 60% stenosis as measured by quan-
titative coronary angiography. The degree of stenosis was
calculated on the basis of the MLD of the stenosis as
compared with the reference diameter of the vessel, that is,
the closest vessel diameter judged to be normal. A successful
angioplasty was defined as less than 50% residual stenosis
and at least 20% reduction of original stenosis.
We defined restenosis as less than 50% luminal diameter
remaining and: 1) at least 20% increase of the stenosis, or 2)
a loss of 0.7 mm or more of the vessel diameter as measured
by quantitative coronary angiography at six months
follow-up procedure when compared with the post-
coronary angioplasty angiography. Acute gain was defined
as the difference between MLD after and before coronary
angioplasty, and late loss was defined as the difference
between MLD after coronary angioplasty and at follow-up
procedure.
Laboratory methods. Blood samples after overnight fast-
ing were obtained 14 and 1 day before, and 3 and 6 months
after balloon treatment.
Serum total cholesterol and triglyceride levels were ana-
lyzed by enzymatic colorimetric methods (Boehringer
Mannheim GmbH, Mannheim, Germany). Serum high-
density lipoprotein cholesterol was determined in the super-
natant after precipitation with phosphotungstic acid and
magnesium chloride (30). Serum samples were kept
frozen at 270°C until analyzed for phospholipid fatty
acids. For each subject, samples obtained at different
times were analyzed in batch. Serum lipids were extracted
with n-butanol after addition of an internal standard
(phosphatidyl-choline diheptadecanoyl, Sigma, St. Louis,
Missouri). An antioxidant (2,6,-di-tert.-butyl-p-kresol,
Fluka AG, Buchs, Switzerland) was added to the n-butanol
before extraction. Phospholipids were isolated from the
total lipid extracts by solid-phase extraction on aminopropyl
columns (Varian, Harbour City, California) and trans-
methylated. The phospholipid fatty acids were quantified by
gas chromatography. FAME mixture Me-81- added C17:0
methylester (Larodan, Malmø, Sweden) was used as an
external standard. A human serum pool sample was in-
cluded as a control to monitor the analytic performance.
The day-to-day coefficients of variation in this serum pool
for C16:0, C18:2n-6, C20:5n-3 and C22:6n-3 were 3.7%,
4.1%, 5.2%, and 4.8%, respectively (n 5 91). The results
were quantified as milligrams of phospholipid fatty acid per
liter of serum. All sera measured had been frozen only once.
The protocol was approved by the Regional Ethics Com-
mittee, and all patients gave their informed consent.
Statistical analysis. The primary end point of the study
was restenosis as determined with quantitative coronary
angiography six months after coronary angioplasty. We
assumed a restenosis rate of 30% per patient in the placebo
group. A sample size of 480 patients was calculated to detect
a 40% relative reduction by fish oil supplementation with a
type I error of 0.05 and a power of 80%.
An increasing use of stenting at the time the study was
designed contributed to the decision to expand the sample
size to 500 patients because stenting was one reason for
exclusion from the study. Analyses were performed after the
intention-to-treat principle. To adjust for interdependency
between multiple restenoses in the same patient, we also
analyzed data with regard to the number of patients with
$1 restenoses within each group.
Variables on categorical data were evaluated by Mantel-
Haenszel test and differences between continuous variables
by the Mann-Whitney U test. A two-sided p value #0.05
was considered statistically significant. Estimation of the
adjusted effect was done by controlling for discrepancies in
risk factors using the multivariate logistic model (31). The
EPI Info software program (32) was used throughout. No
interim analyses were performed.
RESULTS
Table 1 shows the floating scheme of patients throughout
the study. Of the 500 randomized patients, the finally
evaluable population represented 388 patients, 196 assigned
to receive active treatment and 192 constituting the placebo
group. Five patients were withdrawn before admittance to
the catheterization laboratory and 103 patients were dis-
qualified during the coronary angioplasty procedure. The
main reason for this was stenting, which was performed in
54 patients, 25 in the Omacor group and 29 in the placebo
group. In 23 patients the indication for balloon treatment
Table 1. Floating Scheme of Patients Throughout the Study
Study Stages Omacor™ Placebo Total
Patients randomized 250 250 500
Disqualified before coronary
angioplasty
4 1 5
Disqualified during
coronary angioplasty
procedure
49 54 103
Unevaluable dropouts 0 0 0
Deaths in the study period 1 3 4
Evaluable patients 196 192 388
Evaluable stenoses 266 263 529
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was not confirmed when the coronary angiogram was
reevaluated immediately before the planned angioplasty.
Nonsuccessful coronary angioplasty according to the study
protocol was encountered in 23 patients. In addition two
patients were excluded for angiographic reasons (chronic
occlusion, diffuse lesion more than 2 cm) and one patient
because of an alternative treatment.
Finally, four patients died during the study period, two
had acute myocardial infarction before they died, and two
suffered sudden death. The total number of stenoses evalu-
able in the study was 529, 266 in the Omacor group and 263
in the placebo group. As a mean 1.4 stenoses were treated
per patient. One stenosis occurred in 271 patients, 93
patients had two stenoses and 24 patients had three steno-
ses.
From Table 2, which shows the baseline characteristics of
the evaluated patients, we learn that there were no signifi-
cant differences between the two groups concerning age,
gender, smoking habits, diabetes mellitus, hypertension,
previous myocardial infarction, angina pectoris New York
Heart Association (NYHA) class distribution, left ventric-
ular ejection fraction, systolic and diastolic blood pressure.
The only statistically significant difference was in body mass
index (p 5 0.02).
The locations of the index lesions in the coronary arteries
(Table 3) were left anterior descending or one of its side
branches in 39.5%, left circumflex including the intermedi-
ary artery in 34.8% and the right coronary artery in 25.7%.
Lesions in the right coronary artery were somewhat more
frequent in the Omacor than in the placebo group. This
slightly skew distribution did not influence the results of the
trial as the restenosis rates were equal in all locations (data
not shown). There were no group differences in the major
types of lesions (A, B1, B2 and C) when characterized by
the American College of Cardiology/American Heart As-
sociation classification (29).
With respect to the use of relevant drugs at the time of
inclusion, we found no statistically significant differences
between the two groups, with the exception of statins,
which were more frequently used in the placebo group
(Table 4). When the latter difference was analyzed in a
multivariate logistic model, no influence on the crude effect
of Omacor versus placebo on the OR for restenosis was
found.
Table 5 summarizes the dietary intake of energy and main
nutrients at baseline according to a standardized dietary
questionnaire in 261 of the patients. As can be seen the
patients were on a moderate lipid lowering diet with no
clinically important group differences.
When considering serum phospholipid fatty acids and
serum lipids before, two weeks after start of therapy, and six
months after coronary angioplasty (Table 6), EPA, DHA
and total n-3 FA showed significantly increased values in
the Omacor group when compared with the placebo group.
This difference was present already after two weeks. Lino-
Table 2. Baseline Characteristics of the Finally Evaluated 388 Patients According to
Treatment Group
Omacor™
n 5 196
Placebo
n 5 192
p
Value
Age (yr) 60.3 6 9.3 59.1 6 9.3 ns
Male (%) 74.5 80.7 ns
Body mass index (kg/m2) 26.34 6 3.5 25.56 6 3.0 0.02
Smoker (%) 16.3 22.4 ns
Diabetes (%) 7.7 9.4 ns
Treated hypertension (%) 34.2 33.9 ns
Previous myocardial infarction (%) 51 50 ns
NYHA class I (%)* 5.6 2.1
NYHA class II (%)* 39.8 39.6 ns†
NYHA class III (%)* 54.6 58.3
Left ventricular ejection fraction (%) 69 6 13 68 6 14 ns
Systolic blood pressure (mm Hg) 132 6 21 131 6 20 ns
Diastolic blood pressure (mm Hg) 81 6 12 80 6 11 ns
* 5 New York Heart Association classification of angina pectoris. † 5 p value of contingency table.
Values are expressed as mean 6 SD unless otherwise noted. ns 5 not significant.
Table 3. Baseline Lesion Characteristics
Omacor™
n 5 266
Placebo
n 5 263
p
Value
Lesion Location
RCA 81 (30.5%) 55 (20.9%) 0.012
LAD 102 (38.3%) 107 (40.7%) ns
LCx 83 (31.2%) 101 (38.4%) ns
Lesion Type*
A 31 (11.7%) 27 (10.3%) ns
B1 102 (38.3%) 94 (35.7%) ns
B2 94 (35.3%) 106 (40.3%) ns
C 39 (14.7%) 36 (13.7%) ns
*American College of Cardiology/American Heart Association classification (29).
Data presented are number (%) of lesions.
LAD 5 left anterior descending coronary artery; LCx 5 left circumflex coronary
artery; ns 5 not significant; RCA 5 right coronary artery.
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leic acid, arachidonic acid and total n-6 fatty acids were
reduced in the Omacor group. At the same time a consid-
erable and expected reduction in triglycerides was encoun-
tered in the Omacor group whereas no group differences
were found for total cholesterol or high density lipoprotein
cholesterol.
Except for arachidonic acid at two weeks in the placebo
group, total cholesterol at six months in both groups and
triglycerides at six months in the placebo group, all intra-
group differences from baseline were statistically highly
significant (p , 0.01).
Table 7 shows the restenosis rate per patient in the
Omacor group versus the placebo group. As can be seen, no
difference in the incidence of restenoses between the two
groups (46% vs. 45%) was found. The odds ratio (OR) was
1.05 with a 95% confidence interval (CI) ranging from 0.69
to 1.59 (p 5 0.82).
The restenosis rates per treated lesion are also shown in
Table 7. We found the number of restenoses to be 108
(40.6%) in the Omacor group and 93 (35.4%) in the placebo
group, giving an OR of 1.25 with a 95% CI from 0.87 to
1.80 (p 5 0.21). Thus, no difference in the occurrence of
restenosis between Omacor and placebo was found as far as
number of treated stenoses is concerned.
In Table 8 the absolute values of the reference diameter
and the MLD of the index arteries before coronary angio-
plasty, immediately after coronary angioplasty and at
follow-up examination are given. In addition, the acute gain
and late loss are listed. As can be seen no group differences
were found.
Figure 1 illustrates, by visualizing the cumulative distri-
bution curves of the MLDs, that no group differences were
encountered at any time during the study.
Other than three patients in the Omacor group and two
patients in the placebo group with diarrhea or nausea, no
obvious adverse effects to the capsules were noted.
DISCUSSION
Study population: demographics. The present study was a
randomized, double-blind, placebo-controlled trial which
finally evaluated 388 patients who had undergone successful
coronary angioplasty six months earlier. Because of the
study design with randomization at least two weeks before
the coronary angioplasty and an increasing number of
implanted stents, a 20% exclusion rate was calculated. Of
the initially randomized 500 patients, 22.4% were excluded
before or during the coronary angioplasty procedure. The
main reasons were stent implantation (54 patients), lack of
angiographic inclusion criterion on reevaluation before the
coronary angioplasty (23 patients), or unsuccessful coronary
angioplasty according to the study protocol (23 patients).
The excluded patients were evenly distributed between the
treatment groups. Except for four patients who died, no
patient was lost for follow-up procedure. Of the finally
evaluable 388 patients, 196 belonged to the n-3 FA treat-
ment group and 192 to the corn oil placebo group.
The study population was representative of patients
scheduled for elective coronary angioplasty with a mean age
of 60 years, 78% being male, 19% present smokers, 9%
diabetics, 34% treated hypertensives and 50% with previous
myocardial infarction. Furthermore, more than 95% of the
patients had angina pectoris in NYHA class II and III, and
the demographic variables were altogether similar to those
of the meta-analysis of O’Connor et al. (26) and the recent
larger Enoxaparin MaxEPA Prevention of Angioplasty
Restenosis (EMPAR) study (3).
The two groups were also similar in demographic values
as well as in the use of additional drugs at baseline. The only
difference of significance was that statins were used more
often in the placebo group. In multivariate analysis, how-
ever, this difference did not influence the outcome of the
trial with regard to the incidence of restenosis. This finding
Table 4. The Use of Some Relevant Drugs at Baseline Among
the Finally Evaluated 388 Patients According to
Treatment Group
Omacor™
n 5 196
Placebo
n 5 192
p
Value
Betablockers (%) 76.5 72.9 ns
Calcium antagonists (%) 44.9 37.0 ns
Nitrates (%) 72.4 69.3 ns
Angiotensin-converting enzyme
inhibitors (%)
4.1 6.3 ns
Warfarin (%) 18.4 16.1 ns
Aspirin (%) 70.9 67.2 ns
Statins (%) 9.2 16.7 0.03
Fish-oil supplementation (%) 30.6 26.0 ns
ns 5 not significant.
Table 5. Dietary Intake of Energy and Main Nutrients at Baseline According to a Standardized
Dietary Questionnaire (n 5 261) According to Treatment Group
Omacor™
n 5 130
Placebo
n 5 131
p
Value
Energy (kJ) 8,645 (7,218–10,623) 9,216 (7,646–10,657) ns
Carbohydrate % 49.15 (45.70–53.10) 48.40 (44.40–52.60) ns
Protein % 17.5 (16.1–19.1) 17.0 (15.4–18.5) 0.01
Fatty acids % 30.0 (26.5–34.5) 31.5 (27.8–34.4) ns
Median and (Quartiles 25–75%). ns 5 not significant.
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is also in accordance with two recent placebo-controlled
studies, where statins were found to have no effect on the
frequency of restenosis after coronary angioplasty (29,33).
Furthermore, the location and characteristics of the
treated lesions visualize a typical patient population with
severe coronary heart disease admitted for elective coronary
angioplasty in Norway.
Restenosis: definition and effect of n-3 FA. Various
definitions have been used to define restenosis after coronary
angioplasty. The presently used definition with late loss of
minimal luminal diameter of at least 20% or 0.7 mm and
residual diameter of less than 50% have been generally
accepted since the methodological work of Beatt et al. (34).
The observed restenosis rates as judged by quantitative
coronary angiography of approximately 38% when calcu-
lated per stenosis and about 45% per patient are consistent
with those of recent literature and very similar to that
obtained in the EMPAR study (3). This high incidence of
restenosis points to a considerable clinical problem of angina
pectoris after initially successful coronary angioplasty, al-
though the proneness to plaque rupture and myocardial
infarction is probably small in the cellular process of
restenosis with abundant fibrillar collagen (35).
We could not demonstrate any effect on the restenosis
rate of supplementation with 5.1 g/day of highly concen-
trated n-3 FA as compared with placebo. This is not in
accordance with the two meta-analyses published when we
started our study, where a certain positive effect on resten-
osis of n-3 FA was demonstrated (26,27). Thus, O’Connor
et al. (26) found an OR of 0.71 with a 95% CI of 0.54–0.94
for restenosis when supplementation with n-3 FA was
given. In the meta-analysis of Gapinski et al. (27), the
positive effect of n-3 FA on restenosis was mainly present in
the studies where angiographic evaluation of restenosis was
performed and furthermore, positively related to the dosage
of n-3 FA given. Thus, supplementation with more than 4 g
per day was necessary to obtain a positive effect.
However, the results of two larger prospective randomized
placebo-controlled trials on this topic have more lately been
published. Thus, Leaf et al. (4) in their study of 447 evaluable
patients and Cairns et al. (3) with 653 evaluable patients, did
not show any effect of supplementation with 6.9 and 5.4 g/day
of n-3 FA from one–two weeks before the coronary angio-
plasty on the frequency of restenosis after four to six months.
Both studies also used corn oil as placebo, and their results are
very similar to those of our study with regard to the incidence
of restenosis and the lack of effects of supplementation with
n-3 FA. Thus, the meta-analyses of seven smaller studies
probably do not reflect the true effect of supplementation with
n-3 FA on the incidence of restenosis after coronary angio-
plasty. This also stresses the necessity of performing large
controlled trials, and visualizes the discrepancy that may occur
between meta-analyses and larger clinical trials as recently
highlighted by LeLorier et al. (36).
Table 6. Serum Phospholipid Fatty Acids and Serum Lipids Before, Two Weeks and Six Months After Omacor and
Placebo Treatment
Omacor™
n 5 196
Placebo
n 5 192
p
ValueBaseline 2 weeks 6 months Baseline 2 weeks 6 months
Linoleic (18:2n-6)(mg/L) 302 6 80 225 6 62 249 6 70 315 6 69 329 6 67 341 6 70 *†
Arachidonic (20:4n-6)(mg/L) 110 6 31 103 6 26 95 6 24 112 6 33 112 6 35 117 6 33 *†
Eicosapentaenoic (20:5n3)(mg/L) 43 6 31 106 6 32 101 6 36 36 6 25 31 6 20 31 6 21 *†
Docosahexaenoic (22:6n-3)(mg/L) 112 6 36 128 6 29 132 6 30 107 6 32 99 6 29 99 6 30 *†
Total n-3 FA (mg/L) 185 6 68 270 6 61 267 6 66 172 6 57 157 6 50 155 6 52 *†
Total n-6 FA (mg/L) 454 6 112 354 6 89 370 6 93 468 6 96 484 6 93 499 6 95 *†
Total cholesterol (mmol/L) 6.4 6 1.3 6.1 6 1.1 6.3 6 1.2 6.5 6 1.1 6.1 6 1.0 6.4 6 1.1 ns
HDL cholesterol (mmol/L) 1.1 6 0.5 1.1 6 0.3 1.2 6 0.3 1.1 6 0.3 1.1 6 0.3 1.3 6 0.9 ns
Triglycerides (mmol/L) 2.2 6 1.4 1.8 6 1.3 1.6 6 0.9 2.0 6 1.0 2.2 6 1.4 1.9 6 1.1 *†
Mean 6 SD are given. p values refer to group differences in relative changes from baseline at two weeks * and six months †. *†p , 0.001.
HDL 5 high density lipoprotein. ns 5 not significant.
Table 7. Restenosis Rate Per Patient and Per Treated Lesion in the Two Treatment Groups
Omacor™ Placebo Total
Number of patients 196 192 388
Patients with restenosis 90 (45.9%) 86 (44.8%) 176 (45.4%)
OR 5 1.05 (0.69–1.59) p 5 0.82
Number of treated lesions 266 263 529
Lesions with restenoses 108 (40.6%) 93 (35.4%) 201 (38.0%)
OR 5 1.25 (0.87–1.80) p 5 0.21
OR 5 odds ratio with 95% confidence interval in parenthesis.
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Bioavailability of n-3 FA. Concerning patient compliance
to the study medication, the measurements of fatty acids in
the serum phospholipids during the study period are of
special value. The significant increase in EPA and DHA as
well as in the total n-3 FA of 147%, 14% and 46%,
respectively, already at the time of coronary angioplasty
confirm an impressive degree of compliance in the actively
treated patients as a group. For scientific documentation
during supplementation with n-3 FA, such measurements
should be advocated. Leaf et al. (4) obtained this compli-
ance measure as well and showed that, whereas the n-3 FA
were fully present in the plasma phospholipids after 12 days
supplementation, the changes in arachidonic acid, EPA and
DHA in the red cell membrane phospholipids were not yet
completed. The lack of a positive effect of n-3 FA supple-
mentation in our study may still be due to a to short period
of pre-angioplasty supplementation. The study of Bairati et
al. (18) in 119 patients showed a positive result when
supplementation with 4.5 g/day was introduced three weeks
before the coronary angioplasty. However, they did not
measure the n-3 FA concentrations.
The total lack of effect of n-3 FA supplementation in the
recent three large controlled studies (3,4) including our
own, with pretreatment periods of about two weeks, possi-
bly makes it unlikely that the difference in pretreatment
time from two to three weeks plays a dominating role,
although this possibility cannot be completely ruled out.
n-3 FA supplementation: concentrate versus diet. In the
study of Bairati et al. (18) the restenosis rate after coronary
angioplasty was further related to the intake of n-3 FA in
the ordinary diet as evaluated by a quantitative food fre-
quency questionnaire in 103 of the patients. They found a
highly significant relation between the dietary n-3 FA and
the frequency of restenosis with daily content of as little as
0.15 g or more (upper tertile) in the diet, giving an OR of
only 0.20 for restenosis when compared with patients with
a daily intake of less than 0.033 g/day (the lower tertile).
This points to the possibility that n-3 FA, when part of the
ordinary diet, may induce effects that are not visible after
supplementation of n-3 FA in higher concentration.
Whether this possibility will ever be scientifically focused in
larger clinical trials on restenosis after coronary angioplasty
is, however, doubtful.
Conclusions. The present randomized, placebo-controlled
study does not support the hypothesis that supplementation
with n-3 FA concentrate from two weeks before coronary
angioplasty reduces the incidence of restenosis after six
months.
Figure 1. The cumulative distribution curves for minimal luminal diameter expressed as percentage of the number of lesions before
percutaneous transluminal coronary angioplasty, after coronary angioplasty, and at exit follow-up according to treatment group. n-3 FA 5
omega 3-fatty acids.
Table 8. Baseline, Procedural and Follow-up
Angiographic Measurements
Omacor
n 5 266
Placebo
n 5 263
p
Value
Reference Diameter (mm)
before angioplasty 2.8 (2.3–3.3) 2.8 (2.3–3.4) ns
after angioplasty 2.7 (2.3–3.2) 2.7 (2.3–3.3) ns
at follow-up 2.5 (2.2–3.1) 2.5 (2.1–3.1) ns
MLD (mm)
before angioplasty 0.6 (0.3–0.9) 0.5 (0.2–0.8) ns
after angioplasty 2.4 (1.9–3.0) 2.5 (2.1–3.0) ns
at follow-up 1.9 (1.1–2.4) 1.8 (1.3–2.5) ns
Acute Gain (mm) 1.8 (1.4–2.3) 1.9 (1.5–2.4) ns
Late Loss (mm) 0.6 (0.1–1.1) 0.6 (0.1–1.2) ns
Median and (Quartiles 25–75%). MLD 5 minimal luminal diameter; ns 5 not
significant; Acute gain 5 MLD after coronary angioplasty minus MLD before
coronary angioplasty; Late loss 5 MLD after coronary angioplasty minus MLD of
follow-up.
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